Named Bioactive Compounds · Compound
Diosmin (Flavonoid Glycoside)
Strong Evidenceflavonoid
Hermetica Superfood Encyclopedia
Diosmin is a flavonoid glycoside that strengthens venous walls by enhancing vascular endothelial function and reducing capillary permeability. Clinical trials demonstrate it reduces chronic venous disease symptoms by approximately 50%, including pain, swelling, and leg heaviness.
Diosmin is a flavonoid glycoside primarily derived from citrus fruits, especially oranges (Citrus sinensis) and other Citrus species, where it occurs naturally in small amounts. It is typically produced by extracting hesperidin from citrus peels and converting it to diosmin via enzymatic or chemical processes, such as treatment with iodine or benzyl chloride followed by purification.
Clinical evidence includes a multicenter RCT (n=72) showing 450mg bioavailable diosmin significantly improved pain and venous severity scores versus placebo over 8 weeks, and a noninferiority trial (PMID 32206351) demonstrating 600mg nonmicronized diosmin matched 900mg micronized diosmin plus hesperidin for CVD efficacy. A post-surgical RCT (PMID 38109425) found reduced swelling after knee arthroplasty, while an ongoing trial (NCT06125002) is investigating effects on exercise-induced muscle soreness.
Clinically studied doses for chronic venous disease range from 450-900 mg daily, with bioavailable forms (μsmin® Plus) effective at 450 mg once daily, while standard forms use 600 mg once or twice daily. For post-surgical swelling, studies used 600-900 mg daily, and ongoing athletic performance trials are testing 750 mg doses. Consult a healthcare provider before starting any new supplement.
Diosmin is a flavonoid glycoside (molecular formula C₂₈H₃₂O₁₅, MW 608.54 g/mol) and is not a macronutrient source — it provides negligible calories, protein, fat, fiber, or carbohydrates at therapeutic doses. **Bioactive compound:** Diosmin (diosmetin-7-O-rutinoside), a flavone glycoside derived from the aglycone diosmetin (3',5,7-trihydroxy-4'-methoxyflavone) linked to the disaccharide rutinose (rhamnose-glucose). **Typical therapeutic dose:** 450–900 mg/day, most commonly supplied as micronized purified flavonoid fraction (MPFF) containing ~90% diosmin and ~10% other flavonoids (hesperidin, linarin, isorhoifolin, diosmetin). **Natural sources:** Found in citrus peel (especially Citrus sinensis and Citrus limon) at concentrations of ~1–4 mg/g dry weight; also present in Barosma betulina (buchu) and Scrophularia nodosa. Commercially, most diosmin is semi-synthesized from hesperidin (extracted from citrus peels) via catalytic oxidation. **Bioavailability notes:** Native diosmin has very poor oral bioavailability (<10%) due to low aqueous solubility (~0.005 mg/mL). Micronization (particle size reduction to <2 µm) significantly improves absorption, increasing bioavailability approximately 2-fold compared to non-micronized forms. After oral ingestion, diosmin is hydrolyzed by intestinal flora to its aglycone diosmetin, which is the primary absorbed metabolite. Diosmetin undergoes extensive phase II metabolism (glucuronidation and sulfation) in the gut wall and liver. Peak plasma concentrations of diosmetin conjugates occur at ~1–2 hours post-dose for micronized formulations. Plasma half-life of metabolites is approximately 11–31 hours. Urinary recovery of metabolites is ~50% within 48 hours. **Key associated micronutrients in MPFF formulations:** Hesperidin (~10%, ~50–100 mg per dose), which contributes synergistic antioxidant and anti-inflammatory activity. **No significant vitamin or mineral content** at standard supplemental doses.
Diosmin enhances venous tone by increasing norepinephrine sensitivity in venous smooth muscle and inhibiting catechol-O-methyltransferase (COMT) enzyme activity. It reduces capillary permeability by strengthening endothelial tight junctions and decreasing inflammatory mediators like histamine and prostaglandins. The compound also improves lymphatic drainage by stimulating lymphatic contractility and reducing lymphatic vessel hyperpermeability.
A randomized controlled trial with 72 participants over 8 weeks showed diosmin reduced chronic venous disease symptoms by approximately 50%, including significant improvements in pain, swelling, and leg heaviness. A multicenter RCT demonstrated statistically significant improvements in venous clinical severity scores and patient satisfaction (p<0.001). Multiple studies consistently show diosmin effectively reduces lower-extremity swelling and improves overall venous function. The evidence is considered strong for venous insufficiency applications, though most studies have been conducted over relatively short timeframes of 8-12 weeks.
Diosmin is generally well-tolerated with mild gastrointestinal side effects reported in less than 10% of users, including nausea, stomach upset, and diarrhea. No significant drug interactions have been documented in clinical studies, though it may theoretically enhance the effects of anticoagulant medications. Safety during pregnancy and breastfeeding has not been established through controlled studies, so use should be avoided during these periods. Individuals with bleeding disorders should consult healthcare providers before use due to potential effects on vascular function.
